$FOLD, Zacks Rating on Amicus Therapeutics (FOL
Post# of 22756
Posted On: 08/24/2016 8:55:44 AM
$FOLD,
Zacks Rating on Amicus Therapeutics (FOLD)
Michelle Egan By: Michelle Egan|Last Updated: August 24, 2016
Amicus Therapeutics (FOLD) : 5 brokerage houses believe that Amicus Therapeutics (FOLD) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Amicus Therapeutics (FOLD). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 6 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.33.
Amicus Therapeutics (FOLD) stock is expected to deviate a maximum of $3.72 from the average target price of $13.33 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $19 and the most muted being $9.
Amicus
Shares of Amicus Therapeutics, Inc. rose by 5.29% in the last five trading days and 22.83% for the last 4 weeks. Amicus Therapeutics, Inc. is up 3.22% in the last 3-month period. Year-to-Date the stock performance stands at -24.02%. Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Tuesday. Though the stock opened at $7.22, the bulls momentum made the stock top out at $7.555 level for the day. The stock recorded a low of $7.21 and closed the trading day at $7.37, in the green by 2.36%. The total traded volume for the day was 2,023,572. The stock had closed at $7.2 in the previous days trading.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.
Zacks Rating on Amicus Therapeutics (FOLD)
Michelle Egan By: Michelle Egan|Last Updated: August 24, 2016
Amicus Therapeutics (FOLD) : 5 brokerage houses believe that Amicus Therapeutics (FOLD) is a Strong Buy at current levels. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Amicus Therapeutics (FOLD). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 6 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.33.
Amicus Therapeutics (FOLD) stock is expected to deviate a maximum of $3.72 from the average target price of $13.33 for the short term period. 6 Street Experts have initiated coverage on the stock with the most promising target being $19 and the most muted being $9.
Amicus
Shares of Amicus Therapeutics, Inc. rose by 5.29% in the last five trading days and 22.83% for the last 4 weeks. Amicus Therapeutics, Inc. is up 3.22% in the last 3-month period. Year-to-Date the stock performance stands at -24.02%. Amicus Therapeutics (NASDAQ:FOLD): stock turned positive on Tuesday. Though the stock opened at $7.22, the bulls momentum made the stock top out at $7.555 level for the day. The stock recorded a low of $7.21 and closed the trading day at $7.37, in the green by 2.36%. The total traded volume for the day was 2,023,572. The stock had closed at $7.2 in the previous days trading.
Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼